Automated Eye Disease Screening System

自动眼病筛查系统

• 批准号: 8402388
• 负责人: Peter N Soliz
• 金额: $ 59.65万
• 依托单位: VISIONQUEST BIOMEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8402388
• 关键词: Address; Age; Age related macular degeneration; American; Automation; Blindness; Blood Vessels; Businesses; Caring; Centers for Disease Control and Prevention (U.S.); Clinical; Community Healthcare; Computer Assisted; Computer software; Computer-Assisted Diagnosis; Computers; Detection; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Early Diagnosis; Early treatment; Economics; Eye diseases; Fibrinogen; Frequencies; Glaucoma; Goals; Health Personnel; Health Services Accessibility; Healthcare Systems; Human; Hybrids; Hypertension; Image; Image Analysis; Individual; Institutes; Intervention; Joint Ventures; Lesion; Mammography; Manuals; Marketing; Measures; Medical; Medical Imaging; Methods; Microaneurysm; Modeling; New Mexico; Ocular Pathology; Ophthalmic examination and evaluation; Ophthalmologist; Optic Disk; Optometrist; Pallor; Pap smear; Pathology; Phase; Populations at Risk; Productivity; Quality of life; Reader; Reading; Reporting; Research; Research Infrastructure; Research Personnel; Retina; Retinal; Retinal Diseases; Risk; Risk Factors; Safety; Sensitivity and Specificity; Services; Site; Solutions; South Texas; Specialist; Staging; System; Techniques; Technology; Testing; Texas; Time; Training; Universities; Vision; Work; advanced disease; age related; base; clinically significant; commercialization; cost; design; diabetic; image processing; improved; macular edema; meetings; neovascularization; patient safety; programs; proliferative diabetic retinopathy; research and development; screening; success

DESCRIPTION (provided by applicant): This proposed project is motivated by the fact that comprehensive, broad-scale screening for eye diseases such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), including advanced stages, is economically prohibitive without the introduction of computer-assisted diagnosis of retinal images. According to the CDC approximately 80 million people in the U.S. have some form of eye disease, including 20 million diabetics at risk for retinopathy, 60 million at risk for glaucoma, and 13 million diagnosed with AMD. It is estimated that less than half of those individuals with diabetes are screened periodically for DR. Lack of medical coverage and access to healthcare providers imposes major obstacles for nearly 10 million diabetics. Creating an affordable and accessible solution to providing screening services to these diabetics presents a significant challenge to the healthcare community. A comprehensive screening program for U.S. citizens utilizing ophthalmologists, optometrists, or other trained specialists, readers, to grade each case would be prohibitively expensive. The solution is to implement a computer-assisted technology similar to other medical applications, such as mammograms and Pap smears; that would provide comprehensive, periodic screening of our at-risk population. Our business models show a 400% decrease in costs with the integration of automation into today manual screening methods. The study will be made possible through the implementation of the infrastructure for a reading center in South Texas where it is estimated that nearly 200,000 diabetics reside and over 50% do not receive annual examinations. The center will be a demonstration site where the efficacy of the software can be documented for submission to the FDA for pre-market approval (PMA). The goal is to show that a center's through put number of cases screened per time period will increase fivefold through the use of a hybrid (automation-human graders) approach with sensitivity that is comparable or better than solely human-based screening. The significance of this proposed research is two-fold. First, by increasing the productivity of reading centers through automation, a much larger population of at-risk individuals will have access to this service, leading to improved productivity and quality of life through early detection and treatment. Second, by providing to the FDA, a system that is highly effective and sensitive to advanced disease, the issue of safety is essentially eliminated.

描述（由申请人提供）：该拟议项目的动机是，如果不引入计算机辅助的视网膜图像诊断，对年龄相关性黄斑变性（AMD）、青光眼和糖尿病视网膜病变（DR）等眼部疾病（包括晚期阶段）进行全面、大规模的筛查在经济上是令人望而却步的。据 CDC 称，美国大约有 8000 万人患有某种形式的眼病，其中 2000 万糖尿病患者有视网膜病变的风险，6000 万人有青光眼的风险，1300 万人被诊断患有 AMD。据估计，只有不到一半的糖尿病患者定期接受 DR 筛查。缺乏医疗保险和医疗保健提供者的获取给近 1000 万糖尿病患者带来了重大障碍。创建一种负担得起且易于使用的解决方案来为这些糖尿病患者提供筛查服务对医疗保健界来说是一项重大挑战。对于美国公民来说，利用眼科医生、验光师或其他经过培训的专家、读者对每个病例​​进行分级的全面筛查计划将非常昂贵。解决方案是实施类似于其他医疗应用的计算机辅助技术，例如乳房X光检查和子宫颈抹片检查；这将为我们的高危人群提供全面、定期的筛查。通过将自动化集成到当今的手动筛选方法中，我们的业务模型显示成本降低了 400%。这项研究将通过在德克萨斯州南部的一个阅读中心实施基础设施来实现，据估计那里居住着近 200,000 名糖尿病患者，并且超过 50% 的人没有接受年度检查。该中心将成为一个演示站点，可以记录软件的功效，以便提交给 FDA 进行上市前批准 (PMA)。目标是表明，通过使用混合（自动化-人类分级）方法，中心在每个时间段筛查的病例吞吐量将增加五倍，其灵敏度与仅基于人类的筛查相当或更好。这项研究的意义有两方面。首先，通过自动化提高阅读中心的生产力，更多的高危人群将能够获得这项服务，从而通过早期检测和治疗提高生产力和生活质量。其次，通过向 FDA 提供一个对晚期疾病高度有效且敏感的系统，安全问题基本上得到解决。

项目成果

A multiscale decomposition approach to detect abnormal vasculature in the optic disc.

• DOI: 10.1016/j.compmedimag.2015.01.001
• 发表时间: 2015-07
• 期刊: COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
• 影响因子: 5.7
• 作者: Agurto, Carla;Yu, Honggang;Murray, Victor;Pattichis, Marios S.;Nemeth, Sheila;Barriga, Simon;Soliz, Peter
• 通讯作者: Soliz, Peter